TEVA PHARMACEUTICAL INDUSTRIES LTD

Listed Company

TEVACIK 0000818686NYSELarge AcceleratedPharmaceutical PreparationsL3ILFY ends Dec 31

Period

FY 2025

Revenue

$17.26B

Net Income

$1.41B

Total Assets

$40.75B

Equity

$7.91B

Shares Out

1.16B

Op. Cash Flow

$1.65B

Business

Teva Pharmaceutical Industries Ltd is a global pharmaceutical company that develops, manufactures and markets generic, biosimilar and innovative medicines, OTC products, APIs and provides contract manufacturing and distribution services. Its main offerings include a broad portfolio of generic medicines in multiple dosage forms (oral solids, injectables, inhaled products, patches, liquids and topical forms), biosimilars, innovative CNS, respiratory and oncology medicines (e.g., AUSTEDO, AJOVY, COPAXONE, UZEDY, BENDEKA), OTC brands and distribution services. The company operates through three reporting segments—United States, Europe and International Markets—alongside other activities such as API sales, contract manufacturing and an out‑licensing platform. It sells products across North America, Europe, Asia, Latin America and other regions via retail drug chains, mail‑order distributors, wholesalers, hospitals, physician offices and direct commercial channels.

Summary from filing dated 2025-02-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenues	17,258	16,544	15,846	14,925	15,878
Cost of sales	8,320	8,481	8,200	7,952	8,284
Gross profit	8,938	8,064	7,645	6,973	7,594
Research and development expenses, net	1,013	998	953	838	967
Selling and marketing expenses	2,686	2,541	2,336	2,265	2,429
General and administrative expenses	1,287	1,161	1,162	1,180	1,099
Intangible assets impairments	259	251	350	355	424
Goodwill impairment	0	1,280	700	2,045	0
Other asset impairments, restructuring and other items	1,050	1,388	718	512	341
Legal settlements and loss contingencies	467	761	1,043	2,082	717
Other loss (income)	18	−14	−49	−107	−98
Operating income (loss)	2,157	−303	433	−2,197	1,716
Financial expenses net	934	981	1,057	966	1,058
Income (loss) before income taxes	1,223	−1,284	−624	−3,163	658
Income taxes (benefit)	−180	676	−7	−643	211
Share in (profits) losses of associated companies net	−15	−1	−2	−21	−9
Net income (loss)	1,418	−1,959	−615	−2,499	456
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests	7	−320	−56	−53	39
Net income (loss) attributable to Teva	1,410	−1,639	−559	−2,446	417
Basic (per share)	1.23	−1.45	−0.5	−2.2	0.38
Diluted (per share)	1.21	−1.45	−0.5	−2.2	0.38
Basic (shares)	1,145	1,131	1,119	1,110	1,102
Diluted (shares)	1,163	1,131	1,119	1,110	1,107

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2023 2023-06-30
Cash and cash equivalents	3,556	3,300	3,226	—	—
Accounts receivables, net of allowance for credit losses of $81 million and $78 million as of December 31, 2025 and December 31, 2024, respectively	3,709	3,059	3,408	—	—
Inventories	3,179	3,007	4,021	—	—
Prepaid expenses	1,122	1,006	1,255	—	—
Other current assets	539	409	504	—	—
Assets held for sale	1,842	1,771	70	—	—
Total current assets	13,946	12,552	12,485	—	—
Deferred income taxes	2,191	1,799	1,812	1,755	1,583
Other non-current assets	405	462	470	—	—
Property, plant and equipment, net	4,080	4,581	5,750	—	—
Operating lease right-of-use assets	345	367	397	—	—
Identifiable intangible assets, net	3,781	4,418	5,387	—	—
Goodwill	16,000	15,147	17,177	—	—
Total assets	40,748	39,326	43,479	42,095	43,100
Short-term debt	1,820	1,781	1,672	—	—
Sales reserves and allowances	4,143	3,678	3,535	—	—
Accounts payables	2,531	2,203	2,602	—	—
Employee-related obligations	739	624	611	—	—
Accrued expenses	2,687	2,792	2,771	—	—
Other current liabilities	1,182	1,020	1,044	—	—
Liabilities held for sale	354	698	13	—	—
Total current liabilities	13,456	12,796	12,247	—	—
Deferred income taxes	296	483	606	—	—
Other taxes and long-term liabilities	3,808	4,028	4,019	3,950	4,094
Senior notes and loans	14,986	16,002	18,161	—	—
Operating lease liabilities	288	296	320	—	—
Total long-term liabilities	19,379	20,809	23,106	23,314	23,664
Commitments and contingencies, see note 12	—	—	—	—	—
Total liabilities	32,834	33,606	35,353	34,708	35,508
Redeemable non-controlling interests	0	340	0	—	—
Ordinary shares of NIS 0.10 par value per share; December 31, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,257 million shares and 1,240 million shares, respectively	58	58	57	—	—
Additional paid-in capital	28,133	27,764	27,807	—	—
Accumulated deficit	−13,762	−15,173	−13,534	−13,995	−14,066
Accumulated other comprehensive loss	−2,391	−3,148	−2,697	—	—
Treasury shares as of December 31, 2025 and December 31, 2024: 107 million ordinary shares	−4,128	−4,128	−4,128	—	—
Stockholders' equity attributable to Teva shareholders	7,910	5,373	7,506	—	—
Non-controlling interests	4	7	620	—	—
Total equity	7,914	5,380	8,126	7,387	7,592
Total liabilities, redeemable non-controlling interests and equity	40,748	39,326	43,479	42,095	43,100

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Impairment of long-lived assets and assets held for sale	1,028	1,275	378	402	—
Depreciation and amortization	1,002	1,059	1,153	1,308	1,330
Net change in operating assets and liabilities	−1,366	−435	−72	1,355	−1,701
Deferred income taxes net and uncertain tax positions	−671	−634	−317	−1,064	−120
Stock-based compensation	157	123	121	124	119
Net loss (gain) from sale of business and long-lived assets	0	−22	−41	10	104
Other items, net	81	560	61	−91	16
Net cash provided by (used in) operating activities	1,649	1,247	1,368	1,590	798
Beneficial interest collected in exchange for securitized trade receivables	1,214	1,291	1,477	1,140	—
Purchases of property, plant and equipment and intangible assets	−501	−498	−526	−548	−562
Proceeds from sale of business and long lived assets	34	43	68	68	311
Purchases of investments and other assets	−57	−71	−46	−1	−47
Proceeds from sale of investments	42	40	0	4	172
Acquisitions of businesses, net of cash acquired	0	−15	0	−7	0
Other investing activities	5	2	−5	0	1
Net cash provided by (used in) investing activities	737	792	968	656	1,523
Repayment of senior notes and loans and other long term liabilities	−4,112	−1,641	−4,152	−1,369	−6,649
Proceeds from senior notes, net of issuance costs	2,298	0	2,451	0	4,974
Proceeds from short term debt	0	0	700	0	700
Repayment of short term debt	0	0	−700	0	−700
Purchase of shares from redeemable and non-redeemable non-controlling interests	−38	−64	0	0	—
Dividends paid to redeemable and non-redeemable non-controlling interests	−340	−78	0	0	—
Other financing activities	41	−8	−212	−118	−6
Net cash provided by (used in) financing activities	−2,151	−1,791	−1,913	−1,487	−2,172
Translation adjustment on cash, cash equivalents and restricted cash	21	−174	−30	−123	−128
Net change in cash, cash equivalents and restricted cash	256	74	393	636	21
Beneficial interest obtained in exchange for securitized trade receivables	1,278	1,286	1,446	1,189	—
Dividend declared to non-controlling interests	0	0	67	0	0
Interest	950	1,004	1,078	948	913
Other assets	−1,330	−1,104	−1,525	−828	−2,271
Trade payables, accrued expenses, employee-related obligations and other liabilities	−15	258	1,588	2,012	764
Trade receivables net of sales reserves and allowances	−173	245	12	334	−574
Inventories	152	166	−147	−163	380
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	−1,366	−435	−72	1,355	−1,701

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro